

Antibody-Mediated Graft Rejection Market - A Global and Regional Analysis: Focus on Treatment Type, Type of Transplant, and Region - Analysis and Forecast, 2026-2036

<https://marketpublishers.com/r/A5C5A9A78057EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: A5C5A9A78057EN

Abstracts

The global antibody mediated graft rejection market is experiencing significant expansion, driven by the increasing number of organ transplants, advancements in immunosuppressive therapy, and rising awareness of early detection and management of graft rejection. Antibody-mediated rejection (AMR), one of the leading causes of transplant failure, occurs due to the recipient's immune response against donor antigens. Growing emphasis on improving long-term graft survival has led to robust research and clinical development efforts in the antibody mediated graft rejection market, particularly in monoclonal antibodies, intravenous immunoglobulins (IVIG), and complement inhibitors.

The antibody mediated graft rejection market is witnessing increasing demand for effective therapies across kidney, heart, and liver transplants. Expanding organ transplantation programs in the U.S., Europe, and Asia-Pacific, coupled with improved diagnostic techniques such as donor-specific antibody (DSA) testing and C4d staining, are fueling the market's progression. Furthermore, the rise in transplant recipients globally and greater healthcare spending have created a favorable environment for new entrants and biopharmaceutical companies to develop advanced treatment modalities in the antibody mediated graft rejection market.

Major therapeutic approaches driving the antibody mediated graft rejection market include intravenous immunoglobulin, anti-CD20 antibodies, and IL-6 pathway inhibitors, all of which have demonstrated efficacy in reducing alloantibody levels and improving graft function. Continuous R&D investments by pharmaceutical leaders such as F.

Hoffmann-La Roche Ltd, Hansa Biopharma AB, CSL, Biogen, and Sanofi have accelerated innovation within this therapeutic space. Additionally, the emergence of complement inhibitors and plasma exchange therapy is strengthening the treatment pipeline, enhancing the long-term management of chronic AMR cases in the antibody mediated graft rejection market.

The market's growth is further supported by advancements in precision medicine and personalized diagnostics, which enable targeted immunomodulation strategies tailored to patient-specific immunologic profiles. Improved access to transplant care centers and evolving reimbursement frameworks in major economies such as the U.S., U.K., and Germany continue to stimulate growth in the antibody mediated graft rejection market. Moreover, rising collaborations between academic institutions and biotech firms are fostering the discovery of novel therapeutic agents aimed at reducing graft injury and extending transplant longevity.

Despite strong momentum, the antibody mediated graft rejection market faces challenges such as the high cost of biologic therapies, limited availability of transplant immunologists, and complex regulatory approval pathways. Heterogeneity in treatment responses and the need for combination regimens also underscore the necessity for continuous innovation. Nevertheless, technological advancements, coupled with ongoing clinical trials evaluating next-generation biologics and immune tolerance therapies, are expected to address existing unmet needs within the antibody mediated graft rejection market.

The competitive landscape of the antibody mediated graft rejection market is defined by leading biopharmaceutical and biotechnology firms pursuing strategic mergers, acquisitions, and licensing agreements to strengthen their transplant immunotherapy portfolios. Companies are increasingly investing in pipeline expansion and global commercialization efforts to enhance therapeutic accessibility and patient outcomes.

Looking forward, the global antibody mediated graft rejection market is anticipated to maintain steady growth driven by the rising transplantation rate, development of advanced immunotherapies, and improved patient monitoring systems. Integration of AI-driven diagnostic platforms, combined with the continued evolution of targeted biologics, will likely redefine the treatment paradigm of the antibody mediated graft rejection market, improving graft survival and patient quality of life.

Market Segmentation:

Segmentation 1: by Therapy Type

Intravenous Immunoglobulin (IVIg)

Anti-CD20 Antibodies

IL-6 Pathway Inhibitors

Others

Segmentation 2: by Type of Transplant

Kidney Transplant

Heart Transplant

Liver Transplant

Others

Segmentation 3: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

The antibody mediated graft rejection market will continue to evolve through innovations in biologics, combination immunotherapies, and organ transplant diagnostics. Rising global organ transplant volumes, combined with robust R&D initiatives, will shape the antibody mediated graft rejection market as a crucial domain within transplant immunology.

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL ANTIBODY-MEDIATED GRAFT REJECTION MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Ongoing Clinical Trials
1.6 Market Dynamics
 1.6.1 Overview
 1.6.2 Market Drivers
 1.6.3 Market Restraints
 1.6.4 Market Opportunities

2. GLOBAL ANTIBODY-MEDIATED GRAFT REJECTION MARKET, BY TREATMENT TYPE, \$MILLION, 2025-2036

2.1 Intravenous Immunoglobulin
2.2 Anti-CD20 Antibodies
2.3 IL-6 Pathway Inhibitors
2.4 Others

3. GLOBAL ANTIBODY-MEDIATED GRAFT REJECTION MARKET, BY TYPE OF TRANSPLANT, \$MILLION, 2025-2036

3.1 Kidney Transplant
3.2 Heart Transplant
3.3 Liver Transplant
3.4 Others

4. GLOBAL ANTIBODY-MEDIATED GRAFT REJECTION MARKET, BY REGION, \$MILLION, 2025-2036

4.1 North America

4.1.1 Market Dynamics

4.1.2 Market Sizing and Forecast

4.1.3 North America Antibody-Mediated Graft Rejection Market, by Country

4.1.3.1 U.S.

4.2 Europe

4.2.1 Market Dynamics

4.2.2 Market Sizing and Forecast

4.2.3 Europe Antibody-Mediated Graft Rejection Market, by Country

4.2.3.1 U.K.

4.2.3.2 France

4.2.3.3 Germany

4.2.3.4 Italy

4.2.3.5 Spain

4.3 Asia-Pacific

4.3.1 Market Dynamics

4.3.2 Market Sizing and Forecast

4.3.3 Asia-Pacific Antibody-Mediated Graft Rejection Market, by Country

4.3.3.1 Japan

4.3.3.2 China

4.3.3.3 South Korea

4.3.3.4 Australia

4.3.3.5 India

4.4 Rest-of-the-World

4.4.1 Market Dynamics

4.4.2 Market Sizing and Forecast

5. GLOBAL ANTIBODY-MEDIATED GRAFT REJECTION MARKET, COMPETITIVE LANDSCAPE AND COMPANY PROFILES

5.1 Competitive Landscape

5.1.1 Mergers and Acquisitions

5.1.2 Partnership, Alliances and Business Expansion

5.1.3 New Offerings

5.1.4 Regulatory Activities

- 5.1.5 Funding Activities
- 5.2 Company Profiles
 - 5.2.1 F. Hoffmann-La Roche Ltd
 - 5.2.1.1 Overview
 - 5.2.1.2 Top Products / Product Portfolio
 - 5.2.1.3 Top Competitors
 - 5.2.1.4 Target Customers/End-Users
 - 5.2.1.5 Key Personnel
 - 5.2.1.6 Analyst View
 - 5.2.2 Hansa Biopharma AB
 - 5.2.2.1 Overview
 - 5.2.2.2 Top Products / Product Portfolio
 - 5.2.2.3 Top Competitors
 - 5.2.2.4 Target Customers/End-Users
 - 5.2.2.5 Key Personnel
 - 5.2.2.6 Analyst View
 - 5.2.3 CSL
 - 5.2.3.1 Overview
 - 5.2.3.2 Top Products / Product Portfolio
 - 5.2.3.3 Top Competitors
 - 5.2.3.4 Target Customers/End-Users
 - 5.2.3.5 Key Personnel
 - 5.2.3.6 Analyst View
 - 5.2.4 Biogen
 - 5.2.4.1 Overview
 - 5.2.4.2 Top Products / Product Portfolio
 - 5.2.4.3 Top Competitors
 - 5.2.4.4 Target Customers/End-Users
 - 5.2.4.5 Key Personnel
 - 5.2.4.6 Analyst View
 - 5.2.5 Sanofi
 - 5.2.5.1 Overview
 - 5.2.5.2 Top Products / Product Portfolio
 - 5.2.5.3 Top Competitors
 - 5.2.5.4 Target Customers/End-Users
 - 5.2.5.5 Key Personnel
 - 5.2.5.6 Analyst View
 - 5.2.6 Others

6. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Antibody-Mediated Graft Rejection Market (by Scenario), \$Million, 2025, 2030, and 2036

Figure: Global Antibody-Mediated Graft Rejection Market, 2025 and 2036

Figure: Global Antibody-Mediated Graft Rejection Market Key Trends, Impact Analysis

Figure: North America Antibody-Mediated Graft Rejection Market, \$Million, 2025-2036

Figure: Europe Antibody-Mediated Graft Rejection Market, \$Million, 2025-2036

Figure: Asia-Pacific Antibody-Mediated Graft Rejection Market, \$Million, 2025-2036

Figure: Rest-of-the-World Antibody-Mediated Graft Rejection Market, \$Million, 2025-2036

List Of Tables

LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Antibody-Mediated Graft Rejection Market (by Treatment Type), \$Million, 2025-2036

Table: Global Antibody-Mediated Graft Rejection Market (by Type of Transplant), \$Million, 2025-2036

Table: Global Antibody-Mediated Graft Rejection Market (by Region), \$Million, 2025-2036

I would like to order

Product name: Antibody-Mediated Graft Rejection Market - A Global and Regional Analysis: Focus on Treatment Type, Type of Transplant, and Region - Analysis and Forecast, 2026-2036

Product link: <https://marketpublishers.com/r/A5C5A9A78057EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5C5A9A78057EN.html>